Population-level advantage Coyne Scientific offers population-level in vitro toxicity testing using human iPSCs from large donor cohorts, enabling pharma clients to de-risk drug development earlier by predicting human-relevant safety signals across genetic diversity.

Early decision support Their approach helps determine which compounds to deprioritize before animal studies, and which safe compounds might be unfairly flagged, presenting a compelling value prop for cost and timeline reductions in early clinical planning.

Biotech services partner As a dedicated biotech services firm with a new automated 6,500 sq ft lab in Atlanta, CoyneSci can position itself as a compliant, specialized CRO for toxicity and safety pharmacology analyses to pharma and biotech clients.

Industry engagement Leadership and scientists participate in Safety Pharmacology Society, Society of Toxicology, and other global bodies, signaling credibility and opportunities to co-sell or reference in industry-driven initiatives and collaborations.

Technical footprint Leveraging automation, cloud-based workflows, and common tech stacks (WordPress, Google Cloud, analytics) suggests opportunities to optimize client deliverables, reporting dashboards, and scalable project engagements to attract speed-focused sponsors.